HRT does not improve urinary albumin excretion in postmenopausal diabetic women

Manning, Patrick J.; Sutherland, W. H. F.; Allum, Anne R.; Jong, Sylvia A. de; Jones, Stephanie

doi:10.1016/s0168-8227(02)00279-6

Cited by 31 publications

(19 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In postmenopausal women with DM, HRT also did not show any effect on albuminuria compared to women without HRT [48], whereas in premenopausal patients with DM, HRT was clearly associated with albuminuria [43]. Experimental data reveal similar discrepancies as epidemiological studies: in animal models, only continuous application of estrogen throughout a 9-month period was able to reduce experimentally induced glomerulosclerosis, while intermittent application every 3 months had no effect [49].…”

Section: Other Influences Of the Hormonal Milieumentioning

confidence: 85%

The influence of gender and sexual hormones on incidence and outcome of chronic kidney disease

et al. 2011

View full text Add to dashboard Cite

It has long been known that the female sex is associated with a better clinical outcome in chronic renal diseases. Although many experimental, clinical, and epidemiological studies in adults have attempted to explain the difference in disease progression between females and males, a definitive understanding of the underlying mechanisms is still lacking. Hormone-modulating therapies are being increasingly used for various indications (such as post-menopausal hormone replacement, estrogen- or androgen-receptor antagonists for cancer therapy). Therefore, a deeper knowledge of the interaction between sexual hormones and progression of kidney disease is important, as hormone-modulating therapy for non-renal indication may influence both kidney structure and function. In addition, specific modulation of the sexual hormone system, such as the use of selective estrogen receptor modulators, may represent a therapeutic option for patients with renal diseases. Although conclusive data on this topic in the pediatric population are still lacking, the aim of this review is to familiarize pediatric nephrologists with gender-specific differences in renal physiology, pathophysiology, and the progression of kidney diseases. Experimental models that analyze the effects of sexual hormones on renal structure and function are discussed. It is hoped that this review will stimulate researchers to focus on pediatric studies that will provide a deeper insight into the interaction of gender hormones and the kidney both before and during puberty.

show abstract

Section: Other Influences Of the Hormonal Milieumentioning

confidence: 85%

The influence of gender and sexual hormones on incidence and outcome of chronic kidney disease

et al. 2011

View full text Add to dashboard Cite

show abstract

“…Wydaje się, że HTZ nie wpływa negatywnie na te powikłania, czego dowiodły 10-letnie badania przeprowadzone w ramach Wisconsin Epidemiologic Study, w których nie wykazano wpływu tego leczenia na ciężkość retinopatii [25]. W innym badaniu nie wykazano wpływu HTZ na stopień mikroalbuminurii u pacjentek z wieloletnią cukrzycą [26].…”

Section: Hormonalna Terapia Zastępcza U Pacjentek Chorych Na Cukrzycęunclassified

Hormonalna terapia zastępcza a cukrzyca

Wender-Ożegowska¹,

Ożegowska²,

Gutaj³

2013

View full text Add to dashboard Cite

StreszczenieCelem pracy jest przedstawienie poglądów i stanu wiedzy na temat hormonalnej terapii zastępczej (HTZ) u kobiet chorych na cukrzycę.Aktualny stan wiedzy dowodzi, że cukrzyca nie stanowi przeciwwskazania do stosowania HTZ. Dostępne badania wykazały brak jej negatywnego wpływu na kontrolę glikemii, a wręcz wskazują nie tylko na jej korzystny wpływ na gospodarkę węglowodanową, lecz również większości preparatów na profil lipidowy pacjentek. Najkorzystniejszy efekt metaboliczny wydaje się mieć terapia transdermalna z zastosowaniem naturalnego progesteronu lub noretysteronu.Stosowanie HTZ nie wpływa prawdopodobnie korzystnie na profilaktykę jak i leczenie choroby wieńcowej i należy o tym informować pacjentki przed rozpoczęciem terapii.Nie zwalnia to jednak lekarzy z przepisywania tej formy terapii w przypadku stwierdzenia u pacjentki chorej na cukrzycę objawów menopauzalnych bądź ryzyka osteoporozy, bowiem potencjalne negatywne skutki jak i korzyści tej formy terapii są zbliżone do efektów uzyskanych w grupach zdrowych pacjentek. Należy jednak, jak zawsze przy wyborze metody leczenia, zastosować najbezpieczniejszą dla danej pacjentki formę terapii.Słowa kluczowe: hormonalna terapia zastępcza, cukrzyca. SummaryThe purpose of the study is to present today's opinions on hormonal replacement therapy among women with diabetes.Actual knowledge demonstrates that there are no contraindications for HRT in diabetes. This therapy has no adverse effect on glycemic metabolism in diabetic women and selected preparations have a positive effect. Some forms improve the lipid profile in this population. It seems that transdermal therapy containing 17-beta estradiol and natural progesterone or NETA may be the preferable method of treatment recommended for diabetic patients.Nowadays, the use of HRT for the prevention or treatment of CVD is unclear and women should be informed about these data before starting the therapy. This should not stop doctors from prescribing HRT to diabetic women mainly for menopausal symptoms and for the prevention of osteoporosis.On the basis of the data collected so far, however, it is suggested that the risk-benefit ratio is similar to that for the nondiabetic population. A decision whether to prescribe HRT should always be tailored to the individual. Individual assessment of the potential benefits and risks of HRT treatment should be performed for women with diabetes as it is for all women when HRT is considered.

show abstract

“…Cardiovascular protection in healthy premenauposal women is probably due to dual effects of E 2 on VSMC in addition to its other known effects on other cells in the arterial wall and through other factors such as plasma lipoprotein. By contrast, several studies have indicated that a pre-menopausal status does not confer cardiovascular protection in diabetic women [Manning et al, 2003;Scott et al, 2004;Gooding et al, 2005;Bowden et al, 2006;Masding et al, 2006]. Estradiol-17b depletion through menopause or ovariectomy (OVX) leads to altered activity that can be improved by hormone replacement therapy (HRT) which has been reported to modulate vascular function and cardiovascular risk in healthy post-menopausal women.…”

Section: Introductionmentioning

confidence: 99%

The effects of peptides with estrogen‐like activity on cell proliferation and energy metabolism in human derived vascular smooth muscle cells

Sömjen

Knoll

Gayer

et al. 2010

J of Cellular Biochemistry

View full text Add to dashboard Cite

Hormone replacement therapy (HRT) for post-menopausal symptoms in diabetes is associated with increased risk of coronary heart disease and stroke. Therefore, there is a need for new HRT with no adverse effects on diabetic post-menopausal women. We developed peptides as potential estrogen mimetic compounds and now we evaluated the effects of the most efficacious peptide; hexapeptide estrogen-mimetic peptide 1 (EMP-1) (VSWFFE) in comparison to estrogen (E(2)) and peptides with weak activity A44 (KAWFFE) and A45 (KRAFFE) on modulation of cell proliferation of vascular smooth muscle cells (VSMC) growing in normal (ng) or high glucose (hg) concentrations. In ng EMP-1-like E(2) inhibited cell proliferation at high concentration, and stimulated at low concentration. EMP-1 did not affect E(2) stimulation of DNA, but inhibited E(2) inhibition of cell proliferation at high concentration. All effects by the combination of EMP-1 and E(2) were abolished at hg. A44-stimulated cell proliferation at all concentrations and A45 had no effect. When A44 was co-incubated with E(2) at both concentrations, DNA synthesis was stimulated, but abolished at hg. A45 abolished E(2) stimulation and inhibition of cell proliferation at both glucose concentrations. All peptides tested except A45-stimulated CK-specific activity at both glucose concentrations. In hg A44 stimulation of DNA was unaffected as well as its inhibition by EMP-1. EMP-1 and A44 similar to E(2)-stimulated MAPK activity in ng or hg, suggesting similar mechanism of action. The results presented here suggest that EMP-1 provided it acts similarly in vivo can replace E(2) for treatment of post-menopausal women in hyperglycemia due to diabetes.

show abstract

HRT does not improve urinary albumin excretion in postmenopausal diabetic women

Cited by 31 publications

References 40 publications

The influence of gender and sexual hormones on incidence and outcome of chronic kidney disease

The influence of gender and sexual hormones on incidence and outcome of chronic kidney disease

Hormonalna terapia zastępcza a cukrzyca

The effects of peptides with estrogen‐like activity on cell proliferation and energy metabolism in human derived vascular smooth muscle cells

Contact Info

Product

Resources

About